Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology USA
    Guideline Concordant Care and Emerging Data for Patients with MIBC through la/mUC
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, China, France, Germany, India, Italy, Japan, Spain, United Kingdom
    AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug–Drug Interaction Management
    Release Date:
    Review Process: Pfizer Internal
    Research Internal Medicine Australia, Canada, Germany, Greece, Japan, Korea, Taiwan
    Clinical Data Updates on Long Term Outcomes and Practical Therapy Management Strategies in First-line ALK-posit
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology United States Minor Outlying I
    OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology China
    Advancing Adult Immunization Strategies:A Focus on the Impact of Respiratory Syncytial Virus(RSV) and Cardiorespiratory Outcome
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines USA
    Implementing Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease USA
    Transthyretin Cardiac Amyloidosis Fellowship
    Release Date:
    Review Process: Pfizer Internal
    Fellowship Internal Medicine Germany
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Prostate Cancer: Best Practices for Combining Targeted Therapies in mPC
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Transthyretin Cardiac Amyloidosis Fellowship
    Release Date:
    Review Process: Expert Review Panel
    Research Rare Disease USA
    Optimizing Adult Vaccination Ecosystem in India
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines India
    Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic Dermatitis
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Spain
    Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific Antibodies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Spain
    Enhancing HCP Education in Maternal Vaccination
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Saudi Arabia
    Diagnosis and Treatment of Cancer Cachexia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia Areata
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi Arabia
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Saudi Arabia